Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent. The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)
Biomarker and diagnostic research for fibrillary astrocytoma has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
96 publications have been identified in PubMed for fibrillary astrocytoma. Research spans Basic Science / Preclinical (73%), Case Report / Case Series (11%), and Review / Meta-Analysis (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 70 | 73% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:01 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
11 |
11% |
Research summaries | 7 | 7% |
Testing and diagnosis research | 5 | 5% |
Clinical study results | 1 | 1% |
Disease patterns and progression | 1 | 1% |
New treatment approaches | 1 | 1% |
Olopade FE (2026). [PMID: 42128255](https://pubmed.ncbi.nlm.nih.gov/42128255/). *Exp Neurol*. [Basic Science / Preclinical]
Liu Y (2026). [PMID: 42116781](https://pubmed.ncbi.nlm.nih.gov/42116781/). *Zhongguo Zhen Jiu*. [Basic Science / Preclinical]
Sriraksa N (2026). [PMID: 42125768](https://pubmed.ncbi.nlm.nih.gov/42125768/). *Biomed Rep*. [Basic Science / Preclinical]
Zhu F (2026). [PMID: 41647450](https://pubmed.ncbi.nlm.nih.gov/41647450/). *Avicenna journal of phytomedicine*. [Diagnostic / Biomarker]
Yang Y (2026). [PMID: 42153875](https://pubmed.ncbi.nlm.nih.gov/42153875/). *Lymphology*. [Basic Science / Preclinical]
Marotta C (2026). [PMID: 41232216](https://pubmed.ncbi.nlm.nih.gov/41232216/). *Journal of neuroimmunology*. [Case Report / Case Series]
Rahman A (2026). [PMID: 41890479](https://pubmed.ncbi.nlm.nih.gov/41890479/). *Cureus*. [Case Report / Case Series]
Marinescu AM (2026). [PMID: 41317029](https://pubmed.ncbi.nlm.nih.gov/41317029/). *Movement disorders : official journal of the Movement Disorder Society*. [Basic Science / Preclinical]
Kim AR (2026). [PMID: 41947612](https://pubmed.ncbi.nlm.nih.gov/41947612/). *Eur J Oral Sci*. [Basic Science / Preclinical]
Wang MY (2026). [PMID: 41101520](https://pubmed.ncbi.nlm.nih.gov/41101520/). *Neuropharmacology*. [Basic Science / Preclinical]